These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
314 related items for PubMed ID: 10779805
21. Porcine endothelial cells, unlike human endothelial cells, can be killed by human CTL via Fas ligand and cannot be protected by Bcl-2. Zheng L, Ben LH, Pober JS, Bothwell AL. J Immunol; 2002 Dec 15; 169(12):6850-5. PubMed ID: 12471117 [Abstract] [Full Text] [Related]
22. Antigen-dependent release of IFN-gamma by cytotoxic T cells up-regulates Fas on target cells and facilitates exocytosis-independent specific target cell lysis. Müllbacher A, Lobigs M, Hla RT, Tran T, Stehle T, Simon MM. J Immunol; 2002 Jul 01; 169(1):145-50. PubMed ID: 12077239 [Abstract] [Full Text] [Related]
23. Differential contribution of Fas- and perforin-mediated mechanisms to the cell-mediated cytotoxic activity of naive and in vivo-primed intestinal intraepithelial lymphocytes. Corazza N, Müller S, Brunner T, Kägi D, Mueller C. J Immunol; 2000 Jan 01; 164(1):398-403. PubMed ID: 10605035 [Abstract] [Full Text] [Related]
24. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. Williams NS, Engelhard VH. J Immunol; 1996 Jan 01; 156(1):153-9. PubMed ID: 8598456 [Abstract] [Full Text] [Related]
25. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. Delgado M, Ganea D. J Immunol; 2000 Jul 01; 165(1):114-23. PubMed ID: 10861043 [Abstract] [Full Text] [Related]
26. CD4+ T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion. Hombach A, Heuser C, Marquardt T, Wieczarkowiecz A, Groneck V, Pohl C, Abken H. J Immunol; 2001 Jul 15; 167(2):1090-6. PubMed ID: 11441120 [Abstract] [Full Text] [Related]
27. Interferon-gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. Leggatt GR, Dunn LA, De Kluyver RL, Stewart T, Frazer IH. Immunol Cell Biol; 2002 Oct 15; 80(5):415-24. PubMed ID: 12225377 [Abstract] [Full Text] [Related]
28. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms. Kafrouni MI, Brown GR, Thiele DL. J Immunol; 2001 Aug 01; 167(3):1566-74. PubMed ID: 11466378 [Abstract] [Full Text] [Related]
29. Fas ligand-mediated lysis of self bystander targets by human papillomavirus-specific CD8+ cytotoxic T lymphocytes. Smyth MJ, Krasovskis E, Johnstone RW. J Virol; 1998 Jul 01; 72(7):5948-54. PubMed ID: 9621057 [Abstract] [Full Text] [Related]
30. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG, Nencini C, Petrioli R, Prete SP, De Vecchis L, Turriziani M, Giorgi G, Bonmassar E, Francini G. Int J Cancer; 2003 Apr 20; 104(4):437-45. PubMed ID: 12584740 [Abstract] [Full Text] [Related]
31. Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide. Brossart P, Bevan MJ. J Exp Med; 1996 Jun 01; 183(6):2449-58. PubMed ID: 8676065 [Abstract] [Full Text] [Related]
32. Counter-regulation of cytolytic activity and cytokine production in HIV-1-specific murine CD8+ cytotoxic T lymphocytes by free antigenic peptide. Takahashi M, Nakagawa Y, Berzofsky JA, Takahashi H. Int Immunol; 2001 Jan 01; 13(1):43-51. PubMed ID: 11133833 [Abstract] [Full Text] [Related]
33. Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis. Simon MM, Waring P, Lobigs M, Nil A, Tran T, Hla RT, Chin S, Müllbacher A. J Immunol; 2000 Oct 01; 165(7):3663-72. PubMed ID: 11034370 [Abstract] [Full Text] [Related]
34. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. Rivoltini L, Radrizzani M, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Colombo MP, Parmiani G. J Immunol; 1998 Aug 01; 161(3):1220-30. PubMed ID: 9686582 [Abstract] [Full Text] [Related]
35. Self-veto mechanism of CD8+ cytotoxic effector T cells. Peptide-induced paralysis affects the peptide-MHC-recognizing cytotoxic T lymphocytes and is independent of Fas/Fas ligand interactions. Bergenthal A, Hofmann M, Heeg K. Eur J Immunol; 1998 Jun 01; 28(6):1911-22. PubMed ID: 9645373 [Abstract] [Full Text] [Related]
36. Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen. Wizel B, Starcher BC, Samten B, Chroneos Z, Barnes PF, Dzuris J, Higashimoto Y, Appella E, Sette A. J Immunol; 2002 Sep 01; 169(5):2524-35. PubMed ID: 12193722 [Abstract] [Full Text] [Related]
37. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo. Aung S, Graham BS. J Immunol; 2000 Apr 01; 164(7):3487-93. PubMed ID: 10725701 [Abstract] [Full Text] [Related]
38. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI. J Immunol; 2006 Mar 15; 176(6):3374-82. PubMed ID: 16517705 [Abstract] [Full Text] [Related]
39. CD4+CD25+ T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. Janssens W, Carlier V, Wu B, VanderElst L, Jacquemin MG, Saint-Remy JM. J Immunol; 2003 Nov 01; 171(9):4604-12. PubMed ID: 14568934 [Abstract] [Full Text] [Related]
40. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production. Kessler B, Hudrisier D, Schroeter M, Tschopp J, Cerottini JC, Luescher IF. J Immunol; 1998 Dec 15; 161(12):6939-46. PubMed ID: 9862728 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]